Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Acumen Pharmaceuticals announces today the termination by Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.) of a 2003 agreement, amended in 2006, under which Acumen granted Merck exclusive worldwide rights to develop and commercialize anti-ADDL antibody therapeutics and diagnostics for Alzheimer's disease.

Merck's decision to discontinue this anti-ADDL Alzheimer's program and terminate the Merck-Acumen license agreement was based on internal strategic priorities. Under the termination provisions of the agreement, Acumen regains rights licensed to Merck, and also receives certain rights to patent applications and know how generated during the term of the Agreement. Anti-ADDL antibodies have high selectivity for soluble amyloid beta oligomers versus monomeric amyloid beta peptides or insoluble amyloid beta aggregates. Acumen believes this selectivity will favorably differentiate Acumen anti- ADDL immunotherapies compared to amyloid beta immunotherapies currently in late stage clinical testing.

"Acumen is very pleased to regain worldwide rights for the development and commercialization of anti-ADDL antibody therapeutics and diagnostics," stated Grant Krafft, Acumen's Chairman and Chief Science Adviser.

Acumen's Board of Directors also announces the appointment of Franz Hefti, Ph.D. as Acumen's President and CEO. Dr. Hefti has served as a Director of Acumen since 2008 and has a distinguished record in drug development and biotechnology ventures. Dr. Hefti served as Chief Science Officer for Avid Radiopharmaceuticals, which Eli Lilly & Co. acquired in 2010 for its Alzheimer's imaging product, Amyvid™. Prior to Avid, Dr. Hefti was Executive Vice President of Drug Development for Rinat Neuroscience Corporation where he led preclinical and clinical drug development efforts for three antibody drug candidates. The success of these programs led to Pfizer's 2006 acquisition of Rinat.
'/>"/>

SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Boston, MA (PRWEB) April 28, 2015 ... the science of the little-known and incurable disease, ... awarded $485,840 in grants to new projects in the ... and children around the world. , The FSH Society’s ... proposals for the grants. They awarded monies to projects ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 CargoSense, ... company focused on supply chain logistics, today announced ... its seed round, bringing total investment proceeds to ... early stage venture capital firms IrishAngels and Middleburg ... Innovative Technology, also participated in the round. ...
(Date:4/28/2015)... April 28, 2015 Pittcon ... the upcoming Labroots virtual event, Genetics ... The theme of this conference is a ... as RNAi, Next-generation sequencing, cancer research, sequencing, ... genomic medicine, human Genome structural variation, pharmacogenetics, ...
(Date:4/28/2015)... Showcasing continued leadership in the direct ... that provides scientifically advanced, age-defying products, has been ... Association (DSA) by the DSA Board of Directors. ... the DSA confirmed that Nerium’s business practices are ... association: to ensure that direct sales consumers and ...
Breaking Biology Technology:FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 2FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 3FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 4CargoSense Completes Seed Round Offering By Raising $2.5 Million 2CargoSense Completes Seed Round Offering By Raising $2.5 Million 3CargoSense Completes Seed Round Offering By Raising $2.5 Million 4Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 2Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 3Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3
... at American Society of Pharmacognosy, EMERYVILLE, Calif., ... will present seminal information on a new drug ... 7th Annual Oxford International,Conference on the Science of ... April 12-16, 2008. Scott Baggett, Ph.D., a member ...
... April 14 Codexis, Inc. announced,today that it has ... U.S.,Securities and Exchange Commission ("SEC") relating to the proposed ... of the Codexis,registration statement on Form S-1 can be ... shares being offered and the price,range for the offering ...
... and reduced cost for ... pharmaceutical manufacturers, NEW YORK, ... agreement with Chiral Quest, Inc., a manufacturer and,developer of chiral ... chiral products to the pharmaceutical industry., Effective immediately, Sumitomo ...
Cached Biology Technology:Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 2Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... of Standards and Technology (NIST) will no longer provide ... mercury thermometer calibration program marks the end of an ... the doors opened in 1901. The closing of the ... with the U.S. Environmental Protection Agency (EPA) and a ...
... French . Clostridium difficile ... and other health care facilities, but no new drugs to ... a large-scale, phase 3 trial conducted by Canadian and U.S. ... existing treatments, demonstrating a 45 percent reduction in recurrences vs. ...
... , This release is available in German . ... and is extremely precise: within a few seconds, a laser beam ... screws, clamps or glues whatsoever. The result is a perfect weld ... or particles flying through the air during welding. What,s more: the ...
Cached Biology News:End of an era: NIST to cease calibrating mercury thermometers 2First new C. difficile drug in a generation superior to existing treatments: Researchers 2Laser welding in the right light 2
... Neurotransmitters are stored within neurons ... are concentrated in the synaptic bouton. ... isolated from other cellular ... been proposed in many pathological condtions. ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
... the value of your microarray data ... the support you need from consultation ... most up to date methods. Utilize ... Gene Expression Profiling Service or from ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
Biology Products: